PLoS ONE · 2012 · 71 citations · 40 references
Life SciencesCell BiologyPharmacologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingCell Signaling NetworksHormone ReceptorsHormone SignalingSignal Transduction In CancerSteroid Hormone SignalingAgonist ActivityBiphasic Dose-response RelationshipsCell Proliferation StimulationEstrogen PharmacologyEstrogen Receptor SignalingEstrogen ReceptorsMitogenic Signaling DisruptionMitogenic Signaling Pathways
It is prevailingly thought that the antiestrogens tamoxifen and ICI 182, 780 are competitive antagonists of the estrogen-binding site of the estrogen receptor-alpha (ER-α). However, a plethora of evidence demonstrated both antiestrogens exhibit agonist activities in different systems such as activation of the membrane-initiated signaling pathways. The mechanisms by which antiestrogens mediate estrogen-like activities have not been fully established. Previously, a variant of ER-α, EP-α36, has been cloned and showed to mediate membrane-initiated estrogen and antiestrogen signaling in cells only expressing ER-α36. Here, we investigated the molecular mechanisms underlying the antiestrogen signaling in ER-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of endogenous ER-α36. We found that the effects of both 4-hydoxytamoxifen (4-OHT) and ICI 182, 780 (ICI) exhibited a non-monotonic, or biphasic dose response curve; antiestrogens at low concentrations, elicited a mitogenic signaling pathway to stimulate cell proliferation while at high concentrations, antiestrogens inhibited cell growth. Antiestrogens at l nM induced the phosphorylation of the Src-Y416 residue, an event to activate Src, while at 5 µM induced Src-Y527 phosphorylation that inactivates Src. Antiestrogens at 1 nM also induced phosphorylation of the MAPK/ERK and activated the Cyclin D1 promoter activity through the Src/EGFR/STAT5 pathways but not at 5 µM. Knock-down of ER-α36 abrogated the biphasic antiestrogen signaling in these cells. Our results thus indicated that ER-α36 mediates biphasic antiestrogen signaling in the ER-negative breast cancer cells and Src functions as a switch of antiestrogen signaling dependent on concentrations of antiestrogens through the EGFR/STAT5 pathway.
40
Dennis B. Lubahn, Jeffrey S. Moyer, T S Golding et al. · Proceedings of the National Academy of Sciences · 1993 · 1.8K citations · Full text
Medicine, Endocrinology, Genetics +17
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Yongfeng Shang, Xiao Hu, James DiRenzo et al. · Cell · 2000 · 1.7K citations · Full text
A potent specific pure antiestrogen with clinical potential.
A. E. Wakeling, Michael Dukes, Jean Bowler · PubMed · 1991 · 1.1K citations